Medicare Enrolled

Dr. Heidi Jordan, MD

Hematology & Oncology · Grapevine, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
1631 LANCASTER, Grapevine, TX 76051
8172519080
In practice since 2006 (20 years)
NPI: 1386603744 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Jordan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jordan? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Jordan

Dr. Heidi Jordan is a hematology & oncology in Grapevine, TX, with 20 years in practice. Based on federal Medicare data, Dr. Jordan performed 24,197 Medicare services across 2,394 unique beneficiaries.

Between the years covered by Open Payments, Dr. Jordan received a total of $796 from 13 pharmaceutical and/or device companies across 34 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Jordan is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ Top 32% volume in TX$ $796 industry payments

Medicare Practice Summary

Medicare Utilization ↗
24,197
Medicare services
Top 32% in TX for hematology & oncology
2,394
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,210 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron infusion (Feraheme)8,160$0$5
Contrast dye for imaging (iodine-based)4,140$0$3
Iron sucrose injection (Venofer)3,500$0$2
Immune globulin infusion (Octagam)1,944$33$233
Dexamethasone injection (steroid)1,220$0$1
Complete blood count (CBC) with differential693$8$36
Comprehensive metabolic blood panel610$10$64
Blood draw (venipuncture)564$8$20
Injection, granisetron hydrochloride, 100 mcg340$0$24
Office visit, established patient (30-39 min)260$86$368
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less236$22$157
Injection, carboplatin, 50 mg196$2$300
Ferritin level test (iron stores)192$13$60
Iron level test188$6$27
Iron binding capacity test188$9$35
Lactate dehydrogenase (enzyme) level187$6$31
Administration of chemotherapy into vein, 1 hour or less174$102$707
Office visit, established patient, complex (40-54 min)166$129$496
Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3151$20$128
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less89$47$313
Injection, diphenhydramine hcl, up to 50 mg85$1$7
Administration of additional new drug or substance into vein, 1 hour or less77$50$344
Drug injection, under skin or into muscle72$11$96
Injection, zoledronic acid, 1 mg69$6$431
Administration of chemotherapy into vein, each additional hour56$22$161
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle52$56$211
Nuclear medicine study from skull base to mid-thigh with ct scan49$1,121$4,802
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries45$90$657
Ct scan of chest with contrast41$38$821
CT scan of abdomen and pelvis with contrast41$151$1,067
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or41$25$83
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour40$15$100
Unclassified drugs39$1$8
Red blood count automated, with additional calculations38$5$26
Reticulated (young) platelet measurement35$34$143
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg34$316$1,722
Carcinoembryonic antigen (cea) protein level31$19$99
Infusion, normal saline solution , 1000 cc28$2$19
Administration of additional new drug or substance into vein using push technique24$43$289
Red blood cell sedimentation rate, to detect inflammation, non-automated20$4$33
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle20$24$145
Injection of additional new drug or substance into vein19$12$108
CT scan of chest, without contrast18$47$686
Infusion into a vein for hydration, 31-60 minutes14$26$256
Office visit, established patient (20-29 min)11$58$250
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
43.4% high complexity
41.8% medium
14.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$796
Total received (2018-2024)
Avg $133/year across 6 years
Bottom 26% in TX for hematology & oncology
13
Companies
34
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$613 (77.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$183 (23.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$95
2023
$340
2022
$48
2021
$26
2019
$86
2018
$201

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Incyte Corporation
$137
TESARO, Inc.
$124
E.R. Squibb & Sons, L.L.C.
$85
Celgene Corporation
$83
ABBVIE INC.
$80
Siemens Medical Solutions USA, Inc.
$72
Gilead Sciences, Inc.
$52
PFIZER INC.
$51
Pharmacyclics LLC, An AbbVie Company
$41
Janssen Biotech, Inc.
$34
Astellas Pharma US Inc
$14
INSYS Therapeutics Inc
$13
Sirtex Medical Inc
$10
Top 3 companies account for 43.4% of total payments
Associated products mentioned in payments ›
BESPONSA · EPKINLY · ERLEADA · IBRANCE · IMBRUVICA · Imbruvica · JAKAFI · Molecular Accessories · Molecular Reagents/Test Kit/Clinical Utilization · Pomalyst · REBLOZYL · SIR-Spheres Microspheres · SUTENT · SYNDROS · Sotyktu · Trodelvy · XTANDI · Xtandi · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (77%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $3 per 100 Medicare services performed
Looking for a hematology & oncology in Grapevine?
Compare hematology & oncologys in the Grapevine area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncologys nearby

Geographic Context

Hematology & Oncologys within 10 mi
153
Per 100K population
7.2
County median income
$81,905
Nearest hospital
BAYLOR SCOTT & WHITE MEDICAL CENTER GRAPEVINE
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Jordan is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement, with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Jordan experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Jordan performed 8,160 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jordan receive payments from pharmaceutical companies?
Yes. Dr. Jordan received a total of $796 from 13 companies across 34 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jordan's costs compare to other hematology & oncologys in Grapevine?
Dr. Jordan's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jordan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →